Literature DB >> 11457468

Mutations in the genes regulating methylene tetrahydrofolate reductase (MTHFR C-->T677) and cystathione beta-synthase (CBS G-->A919, CBS T-->c833) are not associated with myocardial infarction in African Americans.

A Dilley1, W C Hooper, M El-Jamil, M Renshaw, N K Wenger, B L Evatt.   

Abstract

Moderate hyperhomocysteinemia is a putative risk factor for cardiovascular disease. Molecular studies have demonstrated increased plasma homocysteine levels in the presence of DNA mutations in either the methylenetetrahydrofolate reductase (MTHFR) enzyme found in the remethylation pathway or the enzyme cystathione beta-synthase (CBS) of the transsulfuration pathway. To determine whether the mutation C-->T677 in the MTHFR gene or the T-->C833/844ins68 and G-->A919 mutations in the CBS gene are associated with myocardial infarction (MI) in African Americans, DNA was analyzed from samples obtained from a case-control study conducted at a large, inner-city hospital. One-hundred ten African American subjects with a diagnosis of MI and 185 race- and age-matched controls were recruited. Our results demonstrated that 15% of the MI cases were heterozygous for the C-->T677 (MTHFR) mutation, while 1.8% were homozygous. When compared to the controls in which 15% were heterozygous and 2.1% were homozygous, no significant association with MI was observed. In addition, 34% of the cases were heterozygous for the T-->C833 (CBS) mutation while 6% were homozygous. This is compared to 32% and 5% of the controls having the heterozygous and homozygous genotype, respectively. No significant association was observed for the T-->C833 (CBS) mutation among the cases and controls. Although this mutation has no significant association with MI, the prevalence of the heterozygous state was higher than what has been reported for whites (12%). No mutations for G-->A919 (CBS) were detected in the cases or controls. The racial differences of the CBS T-->C833 polymorphism suggest that further investigation into the other areas of the CBS gene is needed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11457468     DOI: 10.1016/s0049-3848(01)00278-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

1.  Frequency of cystathionine beta-synthase 844INS68 polymorphism in Southern Iran.

Authors:  Sara Senemar; Mehrnoosh Doroudchi; Abdul Mohammad Pezeshki; Masood Bazrgar; Ardeshir Torab-Jahromi; Abbas Ghaderi
Journal:  Mol Biol Rep       Date:  2007-11-29       Impact factor: 2.316

2.  Candidate genetic variants in the fibrinogen, methylenetetrahydrofolate reductase, and intercellular adhesion molecule-1 genes and plasma levels of fibrinogen, homocysteine, and intercellular adhesion molecule-1 among various race/ethnic groups: data from the Women's Genome Health Study.

Authors:  Michelle A Albert; Guillaume Pare; Alanna Morris; Lynda Rose; Julie Buring; Paul M Ridker; Robert Y L Zee
Journal:  Am Heart J       Date:  2009-04       Impact factor: 4.749

3.  Diversity of cystathionine beta-synthase haplotypes bearing the most common homocystinuria mutation c.833T>C: a possible role for gene conversion.

Authors:  Petr Vyletal; Jitka Sokolová; David N Cooper; Jan P Kraus; Michael Krawczak; Guglielmina Pepe; Olga Rickards; Hans G Koch; Michael Linnebank; Leo A J Kluijtmans; Henk J Blom; Godfried H J Boers; Mette Gaustadnes; Flemming Skovby; Bridget Wilcken; David E L Wilcken; Generoso Andria; Gianfranco Sebastio; Eileen R Naughten; Sufin Yap; Toshihiro Ohura; Ewa Pronicka; Aranka Laszlo; Viktor Kozich
Journal:  Hum Mutat       Date:  2007-03       Impact factor: 4.878

4.  The values of AHCY and CBS promoter methylation on the diagnosis of cerebral infarction in Chinese Han population.

Authors:  Xiaodong Li; Shufang Bu; Ran Ran Pan; Cong Zhou; Kun Qu; Xiuru Ying; Jie Zhong; Jianhao Xiao; Qian Yuan; Simiao Zhang; Laura Tipton; Yunliang Wang; Youping Deng; Shiwei Duan
Journal:  BMC Med Genomics       Date:  2020-11-02       Impact factor: 3.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.